Teduglutide
Also called Gattex, Revestive, ALX-0600
Subcutaneous (under the skin)Product label
Research reference
Product label
Gattex short-bowel schedule
0.05 mg/kg once daily; 0.025 mg/kg for specified kidney impairment
Long-term specialist monitoring, not a fixed repair cycle
Gattex product label ↗When results may show
- When change was measured
- Parenteral support, fluid balance, GI examinations and bilirubin/pancreatic laboratory checks require a clinical team.
- When to assess
- Long-term specialist monitoring, not a fixed repair cycle
- Conditions and limitations
- Adults and children age ≥1 with short bowel syndrome requiring parenteral support. Exact kit preparation and baseline screening are necessary. No body-weight-to-fixed-dose conversion or generic mixing instructions are supplied.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Sources: Gattex product label
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Teduglutide describe 3–4 mg per administration. Descriptive only, not a recommendation.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Gattex product labelExact kit preparation and baseline screening are necessary. No body-weight-to-fixed-dose conversion or generic mixing instructions are supplied.